马 越,杜菲菲,王 晶,白小岗,齐 茗.珍芪降糖胶囊联合二甲双胍治疗2型糖尿病的临床疗效研究[J].,2020,(8):1592-1595 |
珍芪降糖胶囊联合二甲双胍治疗2型糖尿病的临床疗效研究 |
Clinical Efficacy of Zhenqi Jiangtang Capsule Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus |
投稿时间:2019-07-28 修订日期:2019-08-23 |
DOI:10.13241/j.cnki.pmb.2020.08.043 |
中文关键词: 珍芪降糖胶囊 二甲双胍 2型糖尿病 临床效果 |
英文关键词: Zhenqi Jiangtang capsule Metformin Type 2 diabetes mellitus Clinical efficacy |
基金项目:陕西省自然科学基础研究计划项目(2018JM4054) |
|
摘要点击次数: 850 |
全文下载次数: 506 |
中文摘要: |
摘要 目的:探讨珍芪降糖胶囊联合二甲双胍治疗2型糖尿病的临床疗效。方法:选取2016年6月-2017年10月延安大学附属医院收取的2型糖尿病患者98例,依据治疗方式不同分为对照组(n=49例)和观察组(n=49例)。对照组在常规治疗基础上结合二甲双胍治疗,观察组在对照组基础上结合珍芪降糖胶囊治疗,对比观察两组临床疗效、治疗前后血糖血脂指标、免疫功能的变化及不良反应的发生情况。结果:治疗后,延安大学附属医院观察组临床总有效率明显优于对照组(91.84%% vs. 71.43%,P<0.05);两组患者的空腹血糖(Fasting Plasma Glucose,FPG)、2 h餐后血糖(2 h Postprandial Blood Glucose,2 h PBG)、糖化血红蛋白(Glycated Hemoglobin,HbA1c)、三酰甘油(Three Acyl Glycerin,TG)、总胆固醇(Total Cholesterol,TC)、高密度脂蛋白胆固醇(High density lipoprotein cholesterol,HDL-C)、低密度脂蛋白胆固醇(Low density lipoprotein cholesterol,LDL-C)、CD8+水平均明显低于治疗前,而HDL-C、CD4+、CD4+/CD8+水平明显高于治疗前,同组内治疗前后对比差异均有显著性(P<0.05);且治疗后观察组FPG、2hPBG、HbA1c、TG、TC、LDL-C、CD8+水平明显低于对照组,HDL-C、CD4+、CD4+/CD8+明显高于对照组,组间治疗后对比差异均有显著性(P<0.05)。两组患者在治疗期间均未出现相关不良反应。结论:珍芪降糖胶囊联合二甲双胍治疗2型糖尿病的临床疗效明显优于单用二甲双胍治疗,其可明显改善患者血糖血脂水平及免疫功能,且安全性高。 |
英文摘要: |
ABSTRACT Objective: To investigate the clinical study of Zhenqi Jiangtang capsule combined with metformin in the treatment of type 2 diabetes mellitus. Methods: 98 patients with type 2 diabetes admitted to our hospital from June 2016 to October 2017 were divided into control group (n=49 cases) and observation group (n=49 cases) according to different treatment methods. The control group was treated with metformin on the basis of routine treatment, while the observation group was treated with Zhenqi Jiangtang Capsule on the basis of the control group. The clinical efficacy, blood glucose and lipid indexes before and after treatment, changes in immune function and adverse reactions of the two groups were compared and observed. Results: Before treatment, there was no significant difference between the two groups in the levels of FPG, 2hPBG, HbA1c, TG, TC, LDL-c, CD8+, CD4+, and CD4+/CD8+ (91.84%% vs. 71.43%, P>0.05). After treatment, the total clinical effective rate of the observation group was significantly better than control group (P<0.05); the levels of FPG, 2H PBG, HbA1c, TG, TC, LDL-C and CD8+ in the two groups were significantly lower than those before treatment, while the levels of HDL-C, CD4+, CD4+/CD8+ were significantly higher than those before treatment, and there was a significant difference between before and after treatment in the same group (P<0.05); and the levels of FPG, 2H PBG, HbA1c, TG, TC, LDL-C and CD8+ in the observation group were significantly lower than control group, while the levels of HDL-C, CD4+, CD4+/CD8+ in the observation group were significantly higher than control group, and there were significant differences between groups after treatment (P<0.05). No adverse reactions occurred during treatment in the two groups. Conclusion: Zhenqi jiangtang capsule combined with metformin in the treatment of type 2 diabetes has a better clinical effect than metformin alone, which can significantly improve the level of blood glucose and lipid levels and the function of immune indicators in patients, and has a significant improvement effect with high safety, which is of clinical significance. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|